Comparative study of the inhalation parameters of COPD patients through NEXThaler® and Ellipta® dry powder inhalers.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 21 12 2023
revised: 01 02 2024
accepted: 19 02 2024
medline: 18 3 2024
pubmed: 26 2 2024
entrez: 25 2 2024
Statut: ppublish

Résumé

The deposition of dry powder aerosol drugs depends on the inhalation parameters of the patients through the inhaler. These data are not directly measured in clinical practice. Their prediction based on the routinely measured spirometric data could help in choosing the appropriate device and optimizing the therapy. The aim of this study was to perform inhalation experiments to find correlations between inhalation parameters of COPD patients through two DPI devices and their native spirometric data, gender, age and disease severity. Another goal was to establish relationships between peak inspiratory flows through NEXThaler® and Ellipta® inhalers and their statistical determinants. Breathing parameters of 113 COPD patients were measured by normal spirometry and while inhaling through the two DPIs. Statistical analysis of the measured data was performed. The average values of peak inspiratory flow through the devices (PIF

Identifiants

pubmed: 38403127
pii: S0954-6111(24)00050-7
doi: 10.1016/j.rmed.2024.107576
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107576

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Alpár Horváth, Gábor Tomisa, Balázs Sánta report a relationship with Chiesi Hungary Kft that includes: employment.

Auteurs

Árpád Farkas (Á)

HUN-REN Centre for Energy Research, Konkoly-Thege Miklós út 29-33, 1121, Budapest, Hungary. Electronic address: farkas.arpad@ek.hun-ren.hu.

Alpár Horváth (A)

Chiesi Hungary Ltd., Dunavirág u. 2, 1138, Budapest, Hungary; Pulmonology Institute of Törökbálint, Munkácsy M. u.70, 2045, Törökbálint, Hungary.

Izolda Réti (I)

Pulmonology Institute of Törökbálint, Munkácsy M. u.70, 2045, Törökbálint, Hungary.

Norbert Ilyés (N)

Pulmonology Institute of Törökbálint, Munkácsy M. u.70, 2045, Törökbálint, Hungary.

Botond Havadtői (B)

Pulmonology Institute of Törökbálint, Munkácsy M. u.70, 2045, Törökbálint, Hungary.

Tamás Kovács (T)

Pulmonology Clinic, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary.

Balázs Sánta (B)

Chiesi Hungary Ltd., Dunavirág u. 2, 1138, Budapest, Hungary.

Gábor Tomisa (G)

Chiesi Hungary Ltd., Dunavirág u. 2, 1138, Budapest, Hungary.

Péter Czaun (P)

Bremotech Ltd., Ezred u. 7, 1044, Budapest, Hungary.

Gabriella Gálffy (G)

Pulmonology Institute of Törökbálint, Munkácsy M. u.70, 2045, Törökbálint, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH